<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773746</url>
  </required_header>
  <id_info>
    <org_study_id>2012-3602</org_study_id>
    <nct_id>NCT01773746</nct_id>
  </id_info>
  <brief_title>Study of Room Air Versus 60% Oxygen for Resuscitation of Premature Infants</brief_title>
  <acronym>PRESOX</acronym>
  <official_title>The Premature Infants Resuscitated With Oxygen or Air (PRESOX) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharp HealthCare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sharp HealthCare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most appropriate initial oxygen concentration for the resuscitation of the extremely low
      birth weight infant has not been established using large well designed, randomized, blinded,
      prospective trials and the level of oxygen utilized by practitioners in this situation is
      highly variable. This proposed trial will use targeted oxygen saturation levels over the
      first 15 to 20 minutes of life to compare a low and a higher initial oxygen level for the
      resuscitation of such infants, and will be large enough to evaluate short term outcomes of
      survival without oxygen at 36 weeks and survival without retinopathy of prematurity, and the
      long term outcome of survival without significant neurodevelopmental impairment at 2 years of
      age. Such information is urgently required to provide an evidence basis for the initial
      oxygen concentration for resuscitation of these very preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Premature Infants Resuscitated with Oxygen or Air (PRESOX) trial, is a prospective
      randomized clinical trial of extremely premature infants that will assess the use of a low
      and high oxygen concentration for the initial resuscitation. The hypothesis is that infants
      resuscitated with a lower oxygen concentration at birth will have a increase in survival
      without bronchopulmonary dysplasia (BPD) or retinopathy of prematurity (ROP) during their
      initial hospitalization, and will have a increase in survival without neurodevelopmental
      impairments.

      Previous studies of mostly term newborn infants have demonstrated that initial resuscitation
      with room air compared to 100% oxygen resulted in improved outcomes and an overall decrease
      in mortality. The analysis of these studies demonstrated that the reduction in mortality was
      very significant in the preterm infants that had been included in these trials. A number of
      small clinical trials have now demonstrated that it is feasible to treat very preterm infants
      with lower versus higher concentrations of oxygen while carefully monitoring their oxygen
      saturation in the minutes following delivery. As review of the previous observations
      demonstrated that there was a reduction in death using lower oxygen concentration, it is
      imperative that a large study of preterm infants be conducted to determine if a lower
      compared to a higher oxygen concentration for the initial resuscitation will lead to improved
      short and longer term outcomes including survival without neurodevelopmental disability.

      The PRESOX trial will randomize infants from 23 weeks gestation to 28 weeks gestation who
      require resuscitation at birth to receive either room air or 60% oxygen. Oxygen saturation
      will be monitored from the first minute of life and the initial oxygen concentration will be
      titrated using a unique purpose built device which will track the oxygen saturation (SpO2)
      within the chosen target limits. The targets chosen allow the infants oxygen saturation to
      follow the increase seen in normal preterm infants who do not require resuscitation.
      Following resuscitation the infants will be transferred to the Neonatal Intensive Care Unit
      and management will follow the usual care in those units. In a subset of infants, levels of
      antioxidants from the infant's blood and urine will be measured by Dr M Vento. This portion
      of the study is already funded by the combined Spanish Ministries of Health and Science.
      Antioxidants are known to increase with exposure to oxygen. The infants will return for a
      neurodevelopmental follow up examination at the age of two years.

      This trial will provide urgently needed evidence to establish the most optimal care to these
      very fragile preterm infants.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival with neurodevelopmental impairment</measure>
    <time_frame>18-22 mos.</time_frame>
    <description>To determine if resuscitation starting with 21% oxygen and a targeted SpO2 strategy will increase survival without significant neurodevelopmental impairment at 18 to 22 months when compared with starting with 60% oxygen and a targeted SpO2 strategy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival without bronchopulmonary dysplasia</measure>
    <time_frame>36 weeks</time_frame>
    <description>2. To determine if resuscitation of extremely low gestational age neonates (ELGAN) starting with 21% oxygen and a targeted SpO2 strategy will increase survival without bronchopulmonary dysplasia when compared with starting with 60% oxygen and a targeted SpO2 strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without ROP</measure>
    <time_frame>36 weeks</time_frame>
    <description>3. To determine if resuscitation of extremely low gestational age neonates (ELGAN) starting with 21% oxygen and a targeted SpO2 strategy will increase survival without Retinopathy of Prematurity when compared with starting with 60% oxygen and a targeted SpO2 strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased GSSG/GSH Ratio</measure>
    <time_frame>Birth,1,3,7 days</time_frame>
    <description>4. To determine if resuscitation starting with 21% oxygen and a targeted SpO2 strategy will result in decreased GSSG/GSH ratio concentrations and decreased production of isofurans when compared with starting with 60% oxygen and a targeted SpO2 strategy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1260</enrollment>
  <condition>Extreme Prematurity - Less Than 28 Weeks</condition>
  <arm_group>
    <arm_group_label>Room Air</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neonatal Resuscitation using continuous positive airway pressure(CPAP) or positive pressure ventilation (PPV) will be provided with 21% oxygen. Infants will remain on 21% oxygen until they have a functioning oximeter when SpO2 will be managed as below. FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60% Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neonatal Resuscitation using CPAP or PPV will be provided with 60% oxygen. Infants will remain on 60% oxygen until they have a functioning oximeter at which time their SpO2 will be managed as described below FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neonatal Resuscitation</intervention_name>
    <description>CPAP or Positive Pressure Ventilation will be provided.</description>
    <arm_group_label>Room Air</arm_group_label>
    <arm_group_label>60% Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Infants with a gestational age of 23 0/7 to 28 6/7 weeks by best obstetrical estimate.

        Infants who will receive full resuscitation as necessary, i.e., no parental request or
        physician decision to forego resuscitation Infants whose parents/legal guardians have
        provided consent for enrollment, or for whom a waiver of consent is in place Infants
        without known major congenital malformations prior to delivery

        Exclusion Criteria:

        Any infant transported to the center after delivery Infants whose parents/legal guardians
        refuse consent Infants born when the research apparatus/study personnel are not available
        Infants &lt; 23 weeks 0 days or &gt; 28 weeks 6 days, completed weeks of gestation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil N Finer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maximo Vento, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe, Valencia Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ola D Saugstad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The National Hospital, Oslo Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wade Rich, RRT, CCRC</last_name>
    <phone>619-543-5375</phone>
    <email>wrich@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy Arnell</last_name>
    <phone>858-939-4966</phone>
    <email>kathy.arnell@sharp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women and Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Arnell, RNC-NIC</last_name>
      <phone>858-939-4966</phone>
      <email>kathy.arnell@sharp.com</email>
    </contact>
    <investigator>
      <last_name>Maynard Rasmussen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-2948</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naveed Hussain, MD</last_name>
      <phone>860-679-2397</phone>
      <phone_ext>4331</phone_ext>
      <email>hussain@nso1.ucnc.edu</email>
    </contact>
    <investigator>
      <last_name>Naveed Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shahnaz Duara, MD</last_name>
      <phone>305-585-6408</phone>
      <email>sduara@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Shahnaz Duara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Edwards, MD</last_name>
      <phone>603-653-6063</phone>
      <email>william.h.edwards@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>William Edwards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mike McCoy, APRN, CNP</last_name>
      <phone>405-271-5215</phone>
      <phone_ext>43006</phone_ext>
      <email>mike-mccoy@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Krishnamurthy Sekar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OU - Tulsa - Saint Francis Hospital</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eden Hemming, MMA</last_name>
      <phone>918-660-3435</phone>
      <email>eden-hemming@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael R Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innsbruck Medical University</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursula Kiechl-Kohlendorfer, MD</last_name>
      <phone>0043 512 504 24309</phone>
      <email>ursula.kohlendorfer@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Ursula Kohlendordfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Prusa, MD</last_name>
      <phone>43 1 40400 5572</phone>
      <email>andrea.prusa@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Andrea Prusa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnold Pollak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anja-Christina Weinhandl</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu-Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte Casper, MD</last_name>
      <phone>33 534558695</phone>
      <email>casper.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Charlotte Casper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulm University</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helmut Hummler, MBA</last_name>
      <phone>0731 50057110</phone>
      <email>helmut.hummler@uniklink-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Helmut Hummler, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Maternity Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colm F O'Donnell, MD</last_name>
      <phone>353 1 637 3100</phone>
      <email>codonnell@nmh.ie</email>
    </contact>
    <investigator>
      <last_name>Colm O'Donnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Ciralli, MD</last_name>
      <phone>00390255032907</phone>
      <email>fabrizio.ciralli@mangiagalli.it</email>
    </contact>
    <investigator>
      <last_name>Fabrizio Ciralli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Siena</name>
      <address>
        <city>Sienna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Buonocore, MD</last_name>
      <phone>0577 586523</phone>
      <email>buonocore@unisi.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Buonocore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Mazela, MD, PhD</last_name>
      <phone>48 618 419270</phone>
      <email>janco@pol-med.com.pl</email>
    </contact>
    <investigator>
      <last_name>Jan Mazela, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Petersberg State Pediatric Medical University</name>
      <address>
        <city>St. Petersberg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aleksei Mostovoi, MD</last_name>
      <phone>79 219896510</phone>
      <email>alvalmost@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aleksei Mostovoi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irena Gantar, MD</last_name>
      <phone>00386 40 154485</phone>
      <email>igantar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Irena Stucin Gantar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cesar W Ruiz-Campillo, MD</last_name>
      <phone>34 93 489 30 39</phone>
      <email>ceruiz@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Cesar W Ruiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Iriondo, MD</last_name>
      <phone>34 932804000</phone>
      <phone_ext>80226</phone_ext>
      <email>miriondo@hsjdbcn.org</email>
    </contact>
    <investigator>
      <last_name>Martin Irionodo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Arruza, MD</last_name>
      <phone>34 628362807</phone>
      <email>luisarruza@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Luiz Arruza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Max Vento, MD</last_name>
      <phone>+34 96 124 5688</phone>
      <email>maximo.vento@uv.es</email>
    </contact>
    <contact_backup>
      <last_name>Pilar Dura</last_name>
      <phone>+34 963 86 27 58</phone>
      <email>gestor_proyectos@iislafe.es</email>
    </contact_backup>
    <investigator>
      <last_name>Maximo Vento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kajsa Bohlin, MD</last_name>
      <phone>46 8 585 813 56</phone>
      <email>kajsa.bohlin@ki.se</email>
    </contact>
    <investigator>
      <last_name>Kajsa Bohlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mithilesh K Lal, MD</last_name>
      <phone>44 1642 282724</phone>
      <email>mithilesh.lal@stees.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mithilesh K Lal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sharp HealthCare</investigator_affiliation>
    <investigator_full_name>Neil Finer</investigator_full_name>
    <investigator_title>Clinical Consultant</investigator_title>
  </responsible_party>
  <keyword>neonatal</keyword>
  <keyword>resuscitation</keyword>
  <keyword>room air</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

